Psyence Biomedical Ltd. (PBM) vs Silexion Therapeutics Ltd. (SLXN)
Over the past year, SLXN lagged PBM — -99.31% vs -73.54% annualized total return (price plus dividends).
A side-by-side comparison of Psyence Biomedical Ltd. and Silexion Therapeutics Ltd. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
Total return — PBM vs SLXN
growth of $100 · dividends reinvested · last 2yMetrics side by side
Did SLXN beat PBM?
Over the past year, SLXN lagged PBM — -99.31% vs -73.54% annualized total return (price plus dividends).
Total return (annualized)
| Metric | PBM | SLXN |
|---|---|---|
| Total return (1Y) | -73.54% | -99.31% |
PBM is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).
Frequently asked
- Has SLXN beaten PBM?
- Over the past year, SLXN lagged PBM — -99.31% vs -73.54% annualized total return (price plus dividends).
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.